| abstract |
(57) Abstract Matrix metalloprotease inhibiting compounds, pharmaceutical preparations thereof and methods of treating diseases using said compounds are described. The compound of the present invention has the general formula (I): In the formula, R 15 is HOCH 2 , MeOCH 2 , (n-Pr) 2 NCH 2 , CH 3 CO 2 CH 2 , EtOCO 2 CH 5 , HO (CH 2 ) 2 , CH 3 CO 2 (CH 2 ) 2 R 16 is selected from the group consisting of: HO 2 C (CH 2 ) 2 , OHC (CH 2 ) 3 , HO (CH 2 ) 4 , Ph, 3-HO-Ph and PhCH 2 OCH 2 ; a) or (b) It is. These compounds are useful for inhibiting matrix metalloproteases and, therefore, pathologies resulting from MMP such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulcer, proteinuria, aortic aneurysm disease Dystrophic epidermolysis bullosa, conditions leading to an inflammatory response, osteopenia mediated by MMP activity, eradication of temporomandibular joint disorders, alleviation of the effects of demyelinating diseases of the nervous system, degeneration due to tumor metastasis or traumatic joint damage It is useful for suppressing cartilage loss and reducing coronary artery thrombus resulting from atherosclerotic plaque rupture. Further, the present invention provides a pharmaceutical preparation and a therapeutic method for treating the above-mentioned medical conditions. |